510 related articles for article (PubMed ID: 31899147)
21. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
[TBL] [Abstract][Full Text] [Related]
22. Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry.
Chong LC; Townsend AR; Young J; Roy A; Piantadosi C; Hardingham JE; Roder D; Karapetis C; Padbury R; Maddern G; Moore J; Price TJ
Target Oncol; 2019 Feb; 14(1):85-91. PubMed ID: 30659494
[TBL] [Abstract][Full Text] [Related]
23. [Analysis of clinicopathological features and prognosis of sporadic synchronous multiple primary colorectal cancers].
Qin ZF; Xu GH; Zhou SQ; Zheng PW; Zhu YP; Ju HX; Li DC; Ma DN
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1171-1178. PubMed ID: 38110279
[No Abstract] [Full Text] [Related]
24. KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer.
Yarom N; Gresham G; Boame N; Jonker D
Clin Colorectal Cancer; 2019 Dec; 18(4):e309-e315. PubMed ID: 31547963
[TBL] [Abstract][Full Text] [Related]
25. KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer.
Nash GM; Gimbel M; Cohen AM; Zeng ZS; Ndubuisi MI; Nathanson DR; Ott J; Barany F; Paty PB
Ann Surg Oncol; 2010 Feb; 17(2):416-24. PubMed ID: 19813061
[TBL] [Abstract][Full Text] [Related]
26. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
27. KRAS mutation in lung metastases from colorectal cancer: prognostic implications.
Ghidini M; Personeni N; Bozzarelli S; Baretti M; Basso G; Bianchi P; Tronconi MC; Pressiani T; Grizzi F; Giordano L; Malesci A; Alloisio M; Laghi L; Santoro A; Rimassa L
Cancer Med; 2016 Feb; 5(2):256-64. PubMed ID: 26715198
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
29. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
[TBL] [Abstract][Full Text] [Related]
30. The association of KRAS mutation with primary tumor location and survival in patients undergoing resection of colorectal cancers and synchronous liver metastases.
Allievi N; Goffredo P; Utria AF; Pisano M; Poiasina E; Lucianetti A; Zhou P; Hassan I
Chin Clin Oncol; 2019 Oct; 8(5):46. PubMed ID: 31500429
[TBL] [Abstract][Full Text] [Related]
31. The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status: A Study By the International Genetic Consortium for Colorectal Liver Metastasis.
Margonis GA; Amini N; Buettner S; Kim Y; Wang J; Andreatos N; Wagner D; Sasaki K; Beer A; Kamphues C; Morioka D; Løes IM; Imai K; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Burkhart R; Endo I; Baba H; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
Ann Surg; 2021 Jun; 273(6):1165-1172. PubMed ID: 31389831
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
33. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
[TBL] [Abstract][Full Text] [Related]
34. Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma.
Rose JS; Serna DS; Martin LK; Li X; Weatherby LM; Abdel-Misih S; Zhao W; Bekaii-Saab T
Cancer; 2012 Dec; 118(24):6243-52. PubMed ID: 22674181
[TBL] [Abstract][Full Text] [Related]
35. Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases.
Margonis GA; Buettner S; Andreatos N; Sasaki K; Ijzermans JNM; van Vugt JLA; Pawlik TM; Choti MA; Cameron JL; He J; Wolfgang CL; Weiss MJ
Ann Surg; 2017 Oct; 266(4):641-649. PubMed ID: 28657938
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients.
Gholami S; Kemeny NE; Boucher TM; Gönen M; Cercek A; Kingham TP; Balachandran V; Allen P; DeMatteo R; Drebin J; Jarnagin W; D'Angelica M
Ann Surg; 2020 Aug; 272(2):352-356. PubMed ID: 32675549
[TBL] [Abstract][Full Text] [Related]
37. Colorectal cancer liver metastases - a population-based study on incidence, management and survival.
Engstrand J; Nilsson H; Strömberg C; Jonas E; Freedman J
BMC Cancer; 2018 Jan; 18(1):78. PubMed ID: 29334918
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases.
Sakai N; Furukawa K; Takayashiki T; Kuboki S; Takano S; Ohtsuka M
BMC Cancer; 2021 Apr; 21(1):412. PubMed ID: 33858364
[TBL] [Abstract][Full Text] [Related]
39. Critical appraisal of surgical margins according to KRAS status in liver resection for colorectal liver metastases: Should surgical strategy be influenced by tumor biology?
Rhaiem R; Duramé A; Primavesi F; Dorcaratto D; Syn N; Rodríguez ÁH; Dupré A; Piardi T; Fernández GB; Villaverde AP; Rodríguez Sanjuán JC; Santiago RF; Fernández-Moreno MC; Ferret G; Ben SL; Suárez Muñoz MÁ; Perez-Alonso AJ; Koh YX; Jones R; Martín-Pérez E; Kianmanesh R; Di Martino M
Surgery; 2024 Jul; 176(1):124-133. PubMed ID: 38519408
[TBL] [Abstract][Full Text] [Related]
40. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N
Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
